Analyst firms · Piper Sandler · CAPR

Piper Sandler CAPR price target and rating history

Capricor Therapeutics Inc. (CAPR) · Health Care

Piper Sandler rates Capricor Therapeutics Inc. (CAPR) Overweight with a $25 price target, as of its latest action on Sep 1, 2026. It has published 3 rating actions on CAPR since October 2024, including 1 upgrade and 1 downgrade. Across 6 firms with a CAPR price target in the last 12 months, the median target is $23. Piper Sandler's $25 is 9% above that.

Current rating
Overweight
Price target
$25
Median target, all firms
$23
Actions on CAPR
3

Piper Sandler price target on CAPR

$35$19$220252026
Piper Sandler price target on CAPR, each point a stated target, October 2024 to September 2026.

Every Piper Sandler rating on CAPR

How other firms rate CAPR

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
B. Riley SecuritiesBuy$21Sep 14, 2026
Piper SandlerOverweight$25Sep 1, 2026
OppenheimerOutperform$54Aug 25, 2026
Cantor FitzgeraldOverweight$28Aug 14, 2026
Maxim GroupHoldJul 30, 2026
H.C. WainwrightNeutralJul 30, 2026
Ladenburg ThalmannNeutralJul 30, 2026
Alliance Global PartnersNeutral$7Jul 28, 2026
Roth CapitalNeutral$7Jul 27, 2026

Questions about Piper Sandler and CAPR

What is Piper Sandler's price target for CAPR?
Piper Sandler's latest stated price target for Capricor Therapeutics Inc. (CAPR) is $25, from its action on Sep 1, 2026.
What is Piper Sandler's rating on CAPR?
Piper Sandler rates CAPR Overweight, a bullish rating, as of Sep 1, 2026.
When did Piper Sandler last change its view on CAPR?
On Sep 1, 2026, Piper Sandler upgrades to Overweight from Neutral, price target $25.
How does Piper Sandler's CAPR target compare with other analysts?
Across 6 firms with a CAPR price target in the last 12 months, the median target is $23. Piper Sandler's $25 is 9% above that.

More CAPR rating histories

All Piper Sandler ratingsCAPR news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.